• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Bringing the drug to market. World practice

16.08.2018/in News /by Evgeniy Makarevich

In more than 150 years of experience in pharmaceuticals, more than 200,000 medicines have been introduced into practice, with two-thirds of them in the last 50 years.

The issue of bringing a new drug to the market worries many market participants. Articles on this subject, reflecting different points of view, come out with an enviable regularity. IMS is also actively involved in the study of this problem.

During the independent research of IMS Health, the eight largest pharmaceutical markets in the world (Canada, Japan, Italy, France, Spain, the USA, England, and Germany) were analyzed, the features of the modern launch of drugs on the market were identified, and also characteristic trends, namely:

– Due to the increase in the number of products, therapeutic classes quickly approach the saturation stage;

– the number of new molecules approved by official authorities (such as the FDA) is declining;

– there are delays in the launch of new drugs, generated by regulatory barriers;

– failure in clinical trials

According to statistics, in recent years, the withdrawal of a significant part of the drugs was suspended. At the same time, many “successfully” launched launches are commercially unsuccessful, some of the recently launched products are recalled due to problems with side effects.

The results of the analysis showed that in recent years, the launch of new products of the main therapeutic classes has had an increasingly less impact on the growth of the pharmaceutical industry.

“Successful” is considered to be drugs that meet the following conditions:

– since the launch, the product continues to receive the market share for 2 years;

– 1-2-rating position in the segment;

– the efficiency of advancement was estimated from the slope of the dynamics curve of market share in the first months after launch.

Of the more than 3000 analyzed launches, only 21 were successful in terms of compliance with the criteria. The percentage of new products that significantly increased their share of the world’s largest markets over a 2-year period is somewhat different.

Examples of successful launches are Lyrica, Spiriva and Cialis preparations. During the first two years of the presence on the market, the products demonstrated faster growth rates of sales volumes, which was reflected in the rapid dynamics of their market shares. The trajectory of growth in the market share of these drugs was very steep. In all major markets, these brands are in the lead.

Many experts of the pharmaceutical market are actively discussing the issue of the successful launch of the drug on the market, trying to analyze the mistakes “before” and “after” the launch and, as a result, to develop key postulates of success.

IMS Health pays attention to the fact that the successful launch of the drug is always well prepared in advance. Based on international experience, a detailed schedule of monthly preparations for launch was developed.

Conclusion

World experience in bringing new drugs to the market once again confirms that launching is always a wide range of activities conducted at various levels of management combined with addressing key issues such as brand positioning, market segmentation, and targeting. The stage of market entry is the first step in the life cycle of a product, its success predetermines the continued existence of the drug on the market, sales, and profits of the manufacturer. Successfully launched drugs, as a rule, become drivers of therapeutic classes, which often has a positive effect on the dynamics of the pharmaceutical market.

Link: www.remedium.ru

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

2 + 6 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
New study finds fake, low-quality medicines prevalent in the developing wor... Ketamine study was stopped due to ethical reasons
Scroll to top